What is GeneDx Holdings's D&A?

GeneDx Holdings (WGS) reported D&A of $6.81M in Q1 2026.

How has GeneDx Holdings's D&A changed year-over-year?

GeneDx Holdings's D&A increased by 19.9% year-over-year, from $5.68M to $6.81M.

What is the long-term trend for GeneDx Holdings's D&A?

Over 4 years (2021 to 2025), GeneDx Holdings's D&A has grown at a 3.7% compound annual growth rate (CAGR), from $21.81M to $25.22M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

GeneDx Holdings WGS D&A

D&A at other companies

Natera, Inc.NTRA

$14.52M+57.2%

Quest DiagnosticsDGX

$147M+5.0%

RevvityRVTY

$105.06M+7.8%

Labcorp HoldingsLH

$173.3M+3.9%

IlluminaILMN

$51M-1.9%

Agilent TechnologiesA

$67M-8.2%

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.72B-24.3%

Enterprise value$1.73B-22.8%

P/S3.9×-3.0×

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAmortizationAndAccretionNet.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's D&A?: GeneDx Holdings (WGS) reported D&A of $6.81M in Q1 2026.
How has GeneDx Holdings's D&A changed year-over-year?: GeneDx Holdings's D&A increased by 19.9% year-over-year, from $5.68M to $6.81M.
What is the long-term trend for GeneDx Holdings's D&A?: Over 4 years (2021 to 2025), GeneDx Holdings's D&A has grown at a 3.7% compound annual growth rate (CAGR), from $21.81M to $25.22M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.